REGENXBIO Inc. Common Stock RGNX
i
Market dataready · fetched 2026-11-07T08:06:51.217Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:24.096047262Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T08:06:50.732244+00:00
REGENXBIO Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 8.15 | 370.1% | 25.3% | |||
| 45Δ | 8.51 | 332.4% | 20.8% | |||
| 50Δ | 8.87 | 294.8% | 16.4% | |||
| 55Δ | 9.14 | 265.5% | 13.2% | |||
| 60Δ | 9.37 | 241.2% | 10.9% | |||
| 65Δ | 9.59 | 216.8% | 8.5% | |||
| 70Δ | 6.83 | 370.3% | 21.8% | 9.81 | 192.5% | 6.2% |
| 75Δ | 6.15 | 305.5% | 12.9% | |||
| 80Δ | 5.78 | 262.1% | 8.7% | 11.66 | 209.7% | 3.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.15
- IV
- 370.1%
- B/E move
- 25.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.51
- IV
- 332.4%
- B/E move
- 20.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.87
- IV
- 294.8%
- B/E move
- 16.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.14
- IV
- 265.5%
- B/E move
- 13.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.37
- IV
- 241.2%
- B/E move
- 10.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.59
- IV
- 216.8%
- B/E move
- 8.5%
70Δ
- Pseudo strike
- 6.83
- IV
- 370.3%
- B/E move
- 21.8%
- Pseudo strike
- 9.81
- IV
- 192.5%
- B/E move
- 6.2%
75Δ
- Pseudo strike
- 6.15
- IV
- 305.5%
- B/E move
- 12.9%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.78
- IV
- 262.1%
- B/E move
- 8.7%
- Pseudo strike
- 11.66
- IV
- 209.7%
- B/E move
- 3.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 193.64% | |
| 210.70% | |
| 194.28% |
Biotechnology
RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is…
More →RLAY
Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.
More →RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the…
More →RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…
More →ROIV
Description unavailable
More →RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New…
More →